Zhejiang Starry Pharmaceutical Co (SHSE:603520) Cash Flow for Dividends: ¥-143 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603520 Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
77 GF Score
Price ¥8.66
GF Value ¥10.94
Valuation Modestly Undervalued
! 9 Warning Signs
View Full Analysis

What is Zhejiang Starry Pharmaceutical Co Cash Flow for Dividends?

Zhejiang Starry Pharmaceutical Co SHSE:603520 +2.61% 77 Cash Flow for Dividends is ¥-143 Mil as of Mar. 2026. GuruFocus rates SHSE:603520 with a GF Score™ of 77/100 and a GF Value™ of ¥10.94 (Modestly Undervalued). The stock has 9 warning signs investors should review.

Zhejiang Starry Pharmaceutical Co's cash flow for dividends for the three months ended in Mar. 2026 was ¥-19 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Mar. 2026 was ¥-143 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Zhejiang Starry Pharmaceutical Co's quarterly payment of dividends declined from Sep. 2025 (¥-39 Mil) to Dec. 2025 (¥-18 Mil) but then increased from Dec. 2025 (¥-18 Mil) to Mar. 2026 (¥-19 Mil).

Zhejiang Starry Pharmaceutical Co's annual payment of dividends declined from Dec. 2023 (¥-196 Mil) to Dec. 2024 (¥-128 Mil) but then increased from Dec. 2024 (¥-128 Mil) to Dec. 2025 (¥-146 Mil).

Zhejiang Starry Pharmaceutical Co Cash Flow for Dividends Related Terms

Zhejiang Starry Pharmaceutical Co Cash Flow for Dividends Historical Data

* Premium members only.

The historical data trend for Zhejiang Starry Pharmaceutical Co's Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zhejiang Starry Pharmaceutical Co Cash Flow for Dividends Chart

Zhejiang Starry Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cash Flow for Dividends
Get a 7-Day Free Trial Premium Member Only Premium Member Only -201.00 -217.60 -195.65 -128.43 -145.98

Zhejiang Starry Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cash Flow for Dividends Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -21.35 -67.90 -38.54 -18.19 -18.59
SHSE:603520
77GF Score
Zhejiang Starry Pharmaceutical Co Ltd SHSE:603520
Cash Flow for Dividends is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zhejiang Starry Pharmaceutical Co Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-143 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Flow for Dividends of ¥-143 Mil mean?
Zhejiang Starry Pharmaceutical Co (SHSE:603520) has a Cash Flow for Dividends of ¥-143 Mil as of Mar. 2026. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Zhejiang Starry Pharmaceutical Co and its competitors.
Is Zhejiang Starry Pharmaceutical Co's Cash Flow for Dividends too high?
Zhejiang Starry Pharmaceutical Co's current Cash Flow for Dividends is ¥-143 Mil. Overall, Zhejiang Starry Pharmaceutical Co has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Starry Pharmaceutical Co's Cash Flow for Dividends compare to ZTS?
Zhejiang Starry Pharmaceutical Co's Cash Flow for Dividends of ¥-143 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow for Dividends for a Drug Manufacturers company?
A good Cash Flow for Dividends depends on the Drug Manufacturers industry context. However, Cash Flow for Dividends should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow for Dividends mean?
A high Cash Flow for Dividends can signal that a stock is expensive relative to its fundamentals. Cash Flow for Dividends represent the amount a company pays as dividends for a specific accounting period. View historical data for Zhejiang Starry Pharmaceutical Co and its competitors. Zhejiang Starry Pharmaceutical Co's current Cash Flow for Dividends is ¥-143 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Starry Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co (SHSE:603520) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥10.94, compared to a current price of ¥8.66 — trading 20.8% below its estimated fair value. The current Cash Flow for Dividends is ¥-143 Mil. Zhejiang Starry Pharmaceutical Co's overall GF Score™ is 77/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow for Dividends calculated?
Cash Flow for Dividends is calculated from a company's financial statements. For Zhejiang Starry Pharmaceutical Co (SHSE:603520), the current Cash Flow for Dividends is ¥-143 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zhejiang Starry Pharmaceutical Co (SHSE:603520) Overvalued in 2026?

Based on GuruFocus' analysis, Zhejiang Starry Pharmaceutical Co stock appears to be undervalued. The current stock price of ¥8.66 is trading 20.8% below its estimated GF Value™ of ¥10.94. GuruFocus considers Zhejiang Starry Pharmaceutical Co to be Modestly Undervalued.

Key valuation signals for SHSE:603520:

  • Cash Flow for Dividends: ¥-143 Mil
  • GF Value™: ¥10.94 vs. price of ¥8.66 (20.8% below fair value)
  • GF Score™: 77/100 with 9 warning signs

No single metric tells the full story. See the SHSE:603520 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zhejiang Starry Pharmaceutical Co Business Description

Address No.1 Sitali Avenue, Modern Industrial Gathering District, Zhejiang Province, Xianju County, Taizhou City, CHN, 317306
Zhejiang Starry Pharmaceutical Co Ltd is engaged in R&D, manufacture and marketing of active ingredient and intermediate X-CT non-ionic contrast agent series and Fluoroquinolones series.
77GF Score

Get the complete analysis for SHSE:603520

Cash Flow for Dividends is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥8.66
Price
¥10.94
GF Value